We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-11.07%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$968M
AUM Growth
-$423M
Cap. Flow
-$289M
Cap. Flow %
-29.89%
Top 10 Hldgs %
92.21%
Holding
21
New
2
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$9.2M
2
PEN icon
Penumbra
PEN
+$4.24M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$103M
2
NVRO
NEVRO CORP.
NVRO
+$43.6M
3
FLXN
Flexion Therapeutics, Inc.
FLXN
+$25.8M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$4.94M
5
AERI
Aerie Pharmaceuticals
AERI
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 55.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$655B
$294M 30.38%
2,979,100
– –
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$199M 20.56%
4,910,487
– –
INGN icon
3
Inogen
INGN
$171M
$172M 17.8%
3,549,320
– –
VGK icon
4
Vanguard FTSE Europe ETF
VGK
$30.1B
$103M 10.68%
2,101,000
– –
NVRO
5
DELISTED
NEVRO CORP.
NVRO
$29M 3%
625,704
-900,000
-59% -$43.6M
TBRA
6
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$26M 2.69%
2,696,405
– –
ADAP
7
DELISTED
Adaptimmune Therapeutics
ADAP
$16.9M 1.75%
1,411,567
-350,000
-20% -$4.94M
OTIC
8
DELISTED
Otonomy, Inc.
OTIC
$15.6M 1.61%
875,025
– –
FLXN
9
DELISTED
Flexion Therapeutics, Inc.
FLXN
$15.4M 1.59%
1,033,131
-1,100,000
-52% -$25.8M
AKBA icon
10
Akebia Therapeutics
AKBA
$343M
$14.6M 1.51%
1,516,387
– –
ELDN icon
11
Eledon Pharmaceuticals
ELDN
$276M
$12.8M 1.32%
7,644
– –
CLCD
12
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$11.8M 1.22%
3,056,563
– –
HTGM
13
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$9.76M 1.01%
7,112
– –
NBRV
14
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$8.24M 0.85%
+3,469
New +$9.2M
PEN icon
15
Penumbra
PEN
$12.6B
$4.21M 0.43%
+104,944
New +$4.24M
GKOS icon
16
Glaukos
GKOS
$8.92B
$1.81M 0.19%
75,000
– –
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.36B
$1.05M 0.11%
127,563
– –
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
– –
-100,000
Closed -$1.76M
ALDR
19
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-1,951,183
Closed -$103M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q3 2015 Portfolio in Review

As of Q3 2015, Novo Holdings A/S held 21 positions worth $968M, down 30% from $1.39B the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Novo Holdings A/S withdrew a net $289M in Q3 2015, closing 2 positions and reducing 3 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $103M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 59% a quarter earlier.

Against the trend, Novo Holdings A/S opened a new position in Nabriva Therapeutics plc Ordinary Shares Ireland worth $8.24M.

  • Novo Holdings A/S's largest Q3 2015 buy was Nabriva Therapeutics plc Ordinary Shares Ireland: 3,469 shares worth $8.24M.
  • Novo Holdings A/S's biggest Q3 2015 reduction was NEVRO CORP., cutting an estimated $43.6M.
  • Novo Holdings A/S fully exited Alder Biopharmaceuticals in Q3 2015, selling an estimated $103M.
  • Novo Holdings A/S's ten largest holdings make up 92% of its $968M portfolio in Q3 2015.
  • Novo Holdings A/S opened 2 new positions and closed 2 in Q3 2015.
  • Novo Holdings A/S's portfolio value fell 30% quarter-over-quarter to $968M.

Based on Novo Holdings A/S's 13F filing for Q3 2015, filed 16 Nov 2015.